注射吸毒者在阿片 agonist 治疗期间丙肝治愈后健康相关生活质量变化
研究纳入141名在纽约布朗克斯3家阿片 agonist 治疗诊所接受丙肝治疗并获得持续病毒学应答的注射吸毒者,使用EQ-5D-3L量表在基线、治疗期间及治疗后多个时间点评估健康相关生活质量。结果显示治疗期间EQ-5D-3L指数显著改善(P < .0001)且治疗后维持,SVR后12周平均指数为0.77(SE = 0.02)。
要点
- 丙肝治愈可改善注射吸毒者阿片 agonist 治疗期间的生活质量。
- 疼痛/不适和焦虑/抑郁问题在SVR后24周分别减少25.7%和24.0%。
- 生活质量改善在治疗结束后至少维持至SVR后12周。
核心结论
- 丙肝治疗使获得SVR的阿片 agonist 治疗中注射吸毒者健康相关生活质量持续改善。
研究设计与样本
- 对141名在纽约布朗克斯3家阿片 agonist 治疗诊所现场接受丙肝治疗并获得SVR的注射吸毒者进行纵向分析。
- 使用EQ-5D-3L量表在基线、治疗第4、8、12周及治疗后第12、24周测量健康相关生活质量。
- 采用线性混合效应回归模型评估EQ-5D-3L指数随时间的变化。
主要发现
- 基线平均EQ-5D-3L指数为0.66(SE = 0.02)。
- 基线时分别有78.0%和66.0%的参与者报告疼痛/不适和焦虑/抑郁问题。
- 治疗后24周,报告疼痛/不适和焦虑/抑郁问题的比例分别下降25.7%和24.0%。
- 治疗期间EQ-5D-3L指数显著改善(P < .0001),SVR后12周平均指数为0.77(SE = 0.02)。
临床怎么用
- 在阿片 agonist 治疗诊所现场提供丙肝治疗可同时改善注射吸毒者的生活质量。
- 关注并管理疼痛/不适和焦虑/抑郁等生活质量问题应纳入丙肝治疗全程。
局限性
- 研究仅纳入获得SVR的注射吸毒者,未报告未获得SVR者的生活质量变化。
- 随访至SVR后12周,更长期的生活质量改善是否维持尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although efforts to treat hepatitis C virus (HCV) in people who inject drugs (PWID) yield high rates of sustained virologic response (SVR), the relationship between successful HCV treatment and health-related quality of life (HRQOL) among PWID is poorly understood. We examined HRQOL changes throughout HCV treatment and post-treatment for PWID achieving SVR. METHODS: Participants included 141 PWID who achieved SVR following HCV treatment onsite at 3 opioid agonist treatment (OAT) clinics in the Bronx, New York. EQ-5D-3L assesses 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), producing an index of HRQOL ranging from 0 to 1. EQ-5D-3L was measured at baseline; 4, 8, and 12 weeks during treatment; and 12 and 24 weeks post-treatment. Linear mixed effects regression models assessed changes in the mean EQ-5D-3L index over time. RESULTS: Mean EQ-5D-3L index baseline was 0.66 (standard error [SE] = 0.02). While over half the population reported no baseline problems with self-care (85.1%), usual activities (56.0%), and mobility (52.5%), at least two-thirds reported problems with pain/discomfort (78.0%) and anxiety/depression (66.0%). Twenty-four weeks post-treatment, proportions reporting pain/discomfort and anxiety/depression decreased by 25.7% and 24.0%, respectively. Mean EQ-5D-3L index significantly improved during treatment (P < .0001), and improvement was sustained following treatment completion, with mean EQ-5D-3L index of 0.77 (SE = 0.02) 12 weeks post-SVR. CONCLUSIONS: HCV treatment led to sustained improvement in HRQOL for PWID on OAT who achieved SVR. Future research is necessary to determine whether improvements in HRQOL can be sustained beyond 12 weeks post-SVR.
引用
- Gormley MA, Akiyama MJ, Rennert L, et al. Changes in Health-related Quality of Life for Hepatitis C Virus-Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response. Clin Infect Dis. 2022. PMID: 34331539. doi:10.1093/cid/ciab669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。